Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MC4R | P32245 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4473196 | 0.85 | NPC1 (0.32) | HSD11B1MEN1ALDH1A1MAPTRAB9A | |
| SCHEMBL4478379 | 0.80 | LMNA (0.34) | HSD11B1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4473145 | 0.74 | DOCK5 (0.34) | HSD11B1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4470762 | 0.73 | CYP11B2 (0.34) | — | |
| SCHEMBL4472455 | 0.65 | SPR (0.34) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4468351 | 0.64 | USP2 (0.31) | MAPT | |
| SCHEMBL4467125 | 0.60 | PTGS1 (0.33) | — | |
| SCHEMBL4462793 | 0.59 | CYP11B2 (0.31) | — | |
| SCHEMBL3054900 | 0.58 | SENP1 (0.50) | MEN1MAPTKMT2ANPSR1 | |
| SCHEMBL8791216 | 0.57 | SMN1; SMN2 (0.81) | HSD11B1HDAC1HDAC8HDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | GALILEO PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | claimed |
| US-7576094-B2 | Spiro derivatives as lipoxygenase inhibitors | ELI LILLY AND COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | GALILEO PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | ALOX15B, ALOX5, ALOX15 | HSD11B1 117/4885HDAC1 1759/4885HDAC8 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.